|Mr. Mariusz Olejniczak||Chief Exec. Officer||45.82k||N/A||N/A|
|Mr. Liam Lake Corcoran||Canadian VP of Legal, Corp. Sec. & Director||69.46k||N/A||N/A|
|Dr. Waldemar Priebe Ph.D.||Founder & Chairman of Scientific Advisory Board||N/A||N/A||N/A|
|Mr. Michael Malana||Chief Financial Officer||N/A||N/A||N/A|
|Ms. Beata Pajak Eng., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Marek Sipowicz M.D., Ph.D.||Chief Medical Officer||N/A||N/A||N/A|
WPD Pharmaceuticals Inc. engages in the research and development of medicinal products in the fields of oncology and infectious disease. Its drug development pipeline includes WPD101 to treat brain cancers, including glioblastoma that is in the pre-clinical trial; WPD102 to treat Uval Melanoma, which is in the pre-clinical trial; Berubicin for the treatment of glioblastoma that us in phase 1 clinical trial; and WP1066 to treat CNS tumors, pancreatic cancer, and ocular tumors, which is in phase 1 clinical trial. The company's drug development pipeline also includes WP1732 for the treatment of pancreatic cancer; WP1220 to treat cutaneous T-cell lymphoma; WPD103 for the treatment of GBM, melanoma, and other cancers that is in the pre-clinical trial; and Annamycin to treat AML and metastasis to lungs, which is in Phase I/II clinical trials in AML. WPD Pharmaceuticals Inc. is based in Vancouver, Canada.
WPD Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.